Elevated serum transaminases in patients with acute coronary syndromes: Do we need a revision of exclusion criteria for clinical trials?
Cardiology Journal · 27.10.2023 · 30 (5) · 747-752
DOI: 10.5603/cj.a2021.0081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiology Journal, online erschienen am 27.10.2023. Verfasst von Małgorzata Jasiewicz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Poland. jasiewiczm@gmail.com. Hauptthemen laut MEDLINE: Acute Coronary Syndrome. Die Arbeit wurde bisher 21-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Elevations of hepatic transaminase (serum alanine transaminase [ALT] and serum aspartate aminotransferase [AST]) levels in patients with acute coronary syndrome (ACS), although transient, may result in exclusions from clinical efficacy trials due to suspected liver disease. The aim of this study was to evaluate the concentrations of serum transaminases in ACS and relate these to currently accepted AST/ALT exclusion criteria from clinical trials. METHODS: One hundred consecutive patients with ACS were prospectively examined. Blood samples for AST, ALT, total bilirubin and troponin I concentration were obtained at the time of admission and after 6, 12 and 24 hours. RESULTS: Eighty percent of patients had elevated AST, and 47% ALT; 43% of patients characterized AST concentration > 3 × upper limit of normal (ULN) in at least one measurement, while 8% of patients presented ALT concentration > 3 × ULN. AST presented higher concentrations when compared to ALT, resulting in a high De-Ritis ratio at every time point. No significant or high correlations were found between the concentrations of serum transaminases, De-Ritis ratio and troponin I. Two different cut-off values of troponin I were adopted to define the amount of infarcted myocardium that distinguished 28-31% of individuals with "large infarction". Among these patients, approximately 93% presented AST concentrations > 3 × ULN. CONCLUSIONS: Hepatic transaminases are often elevated in ACS, with the majority of patients with more extensive myocardial injury presenting high concentrations of AST. In the setting of ACS, current transaminase thresholds for liver dysfunction used in clinical trials may lead to excessive and inadequate exclusions of patients with larger infarcts from such trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Poland. jasiewiczm@gmail.com.
- Department of Health Promotion, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Poland.
- Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Poland.
- Department of Cardiology, Lister Hospital, East and North Hertfordshire National Health Service Trust, Stevenage, United Kingdom.
- Section of Immunology and Hematology, Medical University of Vienna, Austria.
- Department of Cardiology, Medical University of Vienna, Austria.
ORCID-Profile: Małgorzata Jasiewicz, Michał Siedlaczek, Jacek Kubica
Zitieren
APA
Jasiewicz, M., Siedlaczek, M., Kasprzak, M., Gorog, D. A., Jilma, B., Siller-Matula, J., Obońska, K., Dobosiewicz, R., Pstrągowski, K., & Kubica, J. (2023). Elevated serum transaminases in patients with acute coronary syndromes: Do we need a revision of exclusion criteria for clinical trials?. Cardiology Journal, 30(5), 747-752. https://doi.org/10.5603/cj.a2021.0081
Vancouver
Jasiewicz M, Siedlaczek M, Kasprzak M, Gorog DA, Jilma B, Siller-Matula J, et al. Elevated serum transaminases in patients with acute coronary syndromes: Do we need a revision of exclusion criteria for clinical trials?. Cardiology Journal. 2023;30(5):747-752. doi:10.5603/cj.a2021.0081
BibTeX
@article{Jasiewicz2023,
author = {Jasiewicz, Małgorzata and Siedlaczek, Michał and Kasprzak, Michał and Gorog, Diana A and Jilma, Bernd and Siller-Matula, Jolanta and Obońska, Karolina and Dobosiewicz, Ryszard and Pstrągowski, Krzysztof and Kubica, Jacek},
title = {Elevated serum transaminases in patients with acute coronary syndromes: Do we need a revision of exclusion criteria for clinical trials?},
journal = {Cardiology Journal},
year = {2023},
volume = {30},
number = {5},
pages = {747--752},
doi = {10.5603/cj.a2021.0081}
}
EUVIMED